{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-009309","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.023396+00:00","generated_at":"2026-05-15T17:35:46.058050+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988","bullets":["First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.","CDI-988 is a direct-acting oral antiviral targeting 3CL protease; no approved norovirus treatments or vaccines exist.","Study to enroll up to 40 healthy subjects; primary endpoint is reduction of clinical symptoms vs placebo.","CDI-988 previously showed favorable safety in Phase 1; global norovirus economic burden estimated at $60B annually.","FDA issued Study May Proceed Letter in Sep 2025; Emory IRB approval obtained Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-009309","json":"https://secwatch.observer/filing/0001493152-26-009309.json","markdown":"https://secwatch.observer/filing/0001493152-26-009309.md","text":"https://secwatch.observer/filing/0001493152-26-009309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/0001493152-26-009309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:35:46.058050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}